Name: Anti-Human CD4 (Clenoliximab Biosimilar)
Brand: InnoCyto
SKU: 501503
Price: 2000 USD
Availability: InStock

Shop Now Contact

Anti-Human CD4 (Clenoliximab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
501501	1 mg	$250
501502	5 mg	$750
501503	20 mg	$2000

Bulk/Custom

Product Details

Clone	Clenoliximab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Anti-Human CD4 (Clenoliximab Biosimilar)
Isotype	Human IgG4
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human CD4
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Target Name	CD4, T4, Leu3a
Antibody Type	Recombinant
Research Areas	T cells, T cell Activation, Adaptive Immunity
See All Formats	Clone Clenoliximab

Background Information

Clenoliximab is a chimeric monoclonal antibody designed to bind specifically to human CD4, a glycoprotein expressed on the surface of T-helper lymphocytes, monocytes, macrophages, and dendritic cells. Structurally, Clenoliximab belongs to the immunoglobulin G1 (IgG1) subclass and has a molecular weight of approximately 150 kilodaltons (kDa). The antibody is composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds, forming the classical Y-shaped configuration characteristic of immunoglobulins. Each heavy chain contains one variable (VH) domain and three constant (CH1-CH3) domains, whereas each light chain contains one variable (VL) and one constant (CL) domain. The molecule is produced through recombinant DNA technology in mammalian expression systems to ensure proper glycosylation and folding.

The antigen-binding domains of Clenoliximab, contained within its complementarity-determining regions (CDRs), are derived from murine sequences, while the constant regions are of human origin—hence its classification as a chimeric antibody. The murine-derived variable regions confer antigen specificity, enabling high-affinity recognition of the D1 domain of the CD4 receptor. Upon binding, Clenoliximab sterically hinders the interaction between CD4 and major histocompatibility complex class II (MHC-II) molecules on antigen-presenting cells. This blockade modulates receptor-associated signaling processes and alters downstream intracellular activation cascades involving protein kinases and transcription factors such as NF-AT and NF-κB, which govern cytokine production and T-cell proliferation in experimental systems.

The Fc (fragment crystallizable) region of Clenoliximab contributes to molecular stability and prolonged half-life through interaction with neonatal Fc receptors (FcRn). As an IgG1 molecule, it also retains the potential for effector functions, including limited engagement with Fc gamma receptors (FcγRs) and complement components in immune assays. Overall, Clenoliximab illustrates a rationally engineered chimeric IgG1 antibody that combines murine antigen recognition with human structural domains to precisely target and modulate CD4-mediated immune interactions in mechanistic immunological research.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips